About Us
TheraVectys is a spin off from Institut Pasteur with an exclusive and worldwide global Licensing Agreement on Lentiviral Vectors for Vaccine Applications. Profoundly transforming global healthcare and the delivery of effective medicines.
WHAT WE DO
At TheraVectys, we are working to cure and prevent cancers and major infectious diseases.
To fight cancer and diseases such as AIDS, malaria and tuberculosis, efficient cytotoxic T cells, which directly kill infected or tumor cells are required. However, current vaccines and vaccine-candidates fail to achieve the desired result.
Our proprietary lentiviral vector immunotherapy induces unprecedented, high-quality T cell and antibody responses, creating strong and long-term protective or therapeutic immunity.
With many applications, we have an indisputable medicinal path able to save millions of lives.
HOW WE ARE DIFFERENT
Our modified lentiviral vectors have unparalleled properties:
- Non-integrative vectors: Viral DNA does not integrate into the host cell DNA, unlike retroviral vectors.
- DNA flap technology: Enables the virus to cross the nucleus membrane so that genes can be transferred into non-dividing cells.
- Dendritic cell targeting: To elicit a strong, long-standing T cell and antibody-mediated immune response.
WHO WE ARE
TheraVectys is a French-based, leading clinical-stage biotechnology company developing first-in-class lentiviral vector–based vaccine candidates for the prevention and treatment of cancer and infectious diseases. Our proprietary platform is designed to induce sustained cellular immune responses strong enough to break immune tolerance, enabling both therapeutic and prophylactic approaches for diseases with significant unmet needs.
Leveraging a non-integrative, modular design that supports antigen expression without permanent genetic modification of host cells, we can efficiently adapt and scale programs across multiple indications. Our diversified pipeline spans oncology and infectious diseases, including programs targeting HPV-induced cancers (HPV=Human Papillomavirus), HIV, and HBV (Hepatite B), with candidates advancing through clinical development subject to regulatory approvals.
Led by an experienced team of academic and industry veterans, we are pioneering the use of lentiviral vector technology in humans and building a broad portfolio of product candidates at various stages of development.